Phase I Clinical Study in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Condition: HER2-positive Breast Cancer Intervention: Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003. Sponsors: Shanghai Pharmaceuticals Holding Co., Ltd; Shanghai Jiaolian Medicine Research and Development Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials